News
Author: admin als-handoff
-
Achieve Life Sciences Announces Proposed Underwritten Public Offering
SEATTLE, Wash. and VANCOUVER, British Columbia, May 24, 2021 — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced a proposed underwritten public offering in which it intends to offer and sell shares of its common stock….
-
Achieve Reports Financial Results for First Quarter 2021 and Provides Corporate Update
SEATTLE, Wash and VANCOUVER, British Columbia, May 13, 2021 — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced first quarter 2021 financial results and provided an update on the cytisinicline clinical development program. Recent Events &…
-
Achieve Life Sciences to Announce First Quarter 2021 Financial Results and Host Conference Call and Webcast on May 13, 2021
SEATTLE, Wash. and VANCOUVER, British Columbia / ACCESSWIRE / May 4, 2021 / Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that it will report its first quarter 2021 financial results and provide an update on the cytisinicline development program on Thursday, May 13, 2021 at…
-
Achieve Life Sciences, Inc. to Host Virtual Non-Deal Roadshow on Tuesday, April 27, 2021
SEATTLE, Wash and VANCOUVER, British Columbia, April 22, 2021 — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced it will be hosting a Virtual Non-Deal Roadshow on Tuesday, April 27, 2021, at 9:00AM EDT. Achieve’s Chief…
-
Achieve Announces Publication of the ORCA-1 Phase 2b Clinical Trial of Cytisinicline in Adult Smokers in Nicotine and Tobacco Research
Cytisinicline Up to Five Times More Likely to Result in Smoking Abstinence Compared to Placebo. Phase 3 ORCA-2 Trial Currently Enrolling at 16 sites in United States. SEATTLE, Wash and VANCOUVER, British Columbia, April 14, 2021 — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of…